{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T18:00:57Z","timestamp":1771524057660,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jchromb.2025.124890","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T17:26:15Z","timestamp":1764869175000},"page":"124890","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Quantitative LC-MS\/MS Assay for Evocalcet in Human Plasma: Comparative Pharmacokinetic Evaluation in Fasted and Fed Healthy Chinese Volunteers"],"prefix":"10.1016","volume":"1270","author":[{"given":"Keran","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orwa","family":"Siddig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jucui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Dhawelbate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alrazi Eisa","family":"Shogar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinrui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-jun","family":"Hang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2025.124890_bb0005","series-title":"StatPearls Publishing Copyright \u00a9 2025","article-title":"Secondary hyperparathyroidism, in Statpearls","author":"Muppidi","year":"2025"},{"issue":"1","key":"10.1016\/j.jchromb.2025.124890_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/srep19612","article-title":"Pth-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism","volume":"6","author":"Akizawa","year":"2016","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.jchromb.2025.124890_bb0015","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/13543784.2024.2369307","article-title":"Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs","volume":"33","author":"Magagnoli","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"3","key":"10.1016\/j.jchromb.2025.124890_bb0020","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1046\/j.1523-1755.2001.0590031187.x","article-title":"Recent developments in the management of secondary hyperparathyroidism","volume":"59","author":"Goodman","year":"2001","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.jchromb.2025.124890_bb0025","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1744-9987.2008.00648.x","article-title":"Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients","volume":"12","year":"2008","journal-title":"Ther Apher Dial."},{"issue":"15","key":"10.1016\/j.jchromb.2025.124890_bb0030","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jchromb.2025.124890_bb0035","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/j.jrn.2006.04.010","article-title":"Cinacalcet hcl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease","volume":"16","author":"Torres","year":"2006","journal-title":"J. Ren. Nutr."},{"issue":"11","key":"10.1016\/j.jchromb.2025.124890_bb0040","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.clinthera.2005.11.015","article-title":"Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism","volume":"27","author":"Dong","year":"2005","journal-title":"Clin. Ther."},{"issue":"5","key":"10.1016\/j.jchromb.2025.124890_bb0045","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/17446651.2020.1780911","article-title":"Development of evocalcet for unmet needs among calcimimetic agents","volume":"15","author":"Hamano","year":"2020","journal-title":"Expert. Rev. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.jchromb.2025.124890_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195316","article-title":"A novel calcimimetic agent, evocalcet (mt-4580\/khk7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or cyp isozymes in vivo and in vitro","volume":"13","author":"Kawata","year":"2018","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.jchromb.2025.124890_bb0055","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1016\/j.ekir.2021.08.020","article-title":"Efficacy of evocalcet in previously cinacalcet-treated secondary hyperparathyroidism patients","volume":"6","author":"Koiwa","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"3","key":"10.1016\/j.jchromb.2025.124890_bb0060","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/1744-9987.13434","article-title":"Evocalcet: a new oral calcimimetic for dialysis patients with secondary hyperparathyroidism","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther. Apher. Dial."},{"issue":"4","key":"10.1016\/j.jchromb.2025.124890_bb0065","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/1744-9987.14125","article-title":"Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: a systematic review and meta-analysis of randomized studies","volume":"28","author":"Nakai","year":"2024","journal-title":"Ther. Apher. Dial."},{"issue":"10","key":"10.1016\/j.jchromb.2025.124890_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204896","article-title":"Phase 2b study of evocalcet (khk7580), a novel calcimimetic, in japanese patients with secondary hyperparathyroidism undergoing hemodialysis: a randomized, double-blind, placebo-controlled, dose-finding study","volume":"13","author":"Akizawa","year":"2018","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.jchromb.2025.124890_bb0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1254\/fpj.154.35","article-title":"Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (orkedia(\u00ae))","volume":"154","author":"Tokunaga","year":"2019","journal-title":"Nihon Yakurigaku Zasshi."},{"key":"10.1016\/j.jchromb.2025.124890_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116473","article-title":"Pharmacovigilance of drug-drug interactions: a pharmacokinetic study on the combined oral administration of lurasidone and clozapine in rats by using lc-ms\/ms","volume":"252","author":"Siddig","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"10","key":"10.1016\/j.jchromb.2025.124890_bb0085","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s40261-018-0687-4","article-title":"Pharmacokinetics, pharmacodynamics, and safety of the novel calcimimetic agent evocalcet in healthy japanese subjects: first-in-human phase i study","volume":"38","author":"Akizawa","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.jchromb.2025.124890_bb0090","first-page":"101","article-title":"Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan","volume":"10","author":"Shigematsu","year":"2018","journal-title":"Clin Pharmacol."},{"key":"10.1016\/j.jchromb.2025.124890_bb0095","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2147\/DDDT.S437903","article-title":"Pharmacokinetics, pharmacodynamics, and safety of evocalcet (khk7580), a novel calcimimetic agent: an open-label, single- and multiple-dose, phase i trial in healthy chinese subjects","volume":"18","author":"He","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jchromb.2025.124890_bb0100","author":"S.M.H. European Medicines Agency"},{"issue":"1","key":"10.1016\/j.jchromb.2025.124890_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245785","article-title":"The effect of evocalcet on vagus nerve activity of the gastrointestinal tract in miniature pigs","volume":"16","author":"Tokunaga","year":"2021","journal-title":"PloS One"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225004441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225004441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T17:00:34Z","timestamp":1771520434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023225004441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":21,"alternative-id":["S1570023225004441"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124890","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative LC-MS\/MS Assay for Evocalcet in Human Plasma: Comparative Pharmacokinetic Evaluation in Fasted and Fed Healthy Chinese Volunteers","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124890","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124890"}}